menu search

CYCC / Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis
Cyclacel Pharmaceuticals is an oncology company with two major value drivers in Phase 1/2 trials and overdue catalysts. It trades at an $11 million market cap, with last reported cash of $34.5 million, and mean analyst estimate shows a +1,500% rise potential. Read More
Posted: Aug 7 2022, 09:53
Author Name: Seeking Alpha
Views: 111148

CYCC News  

New Strong Buy Stocks for October 17th

By Zacks Investment Research
October 17, 2023

New Strong Buy Stocks for October 17th

MNTX, PGNY, GFF, RKDA and CYCC have been added to the Zacks Rank #1 (Strong Buy) List on October 17, 2023. more_horizontal

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

By GlobeNewsWire
March 7, 2023

Cyclacel Pharmaceuticals to Participate in March Investor Conferences

BERKELEY HEIGHTS, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), more_horizontal

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

By Seeking Alpha
August 7, 2022

Cyclacel: Trading At Less Than Half Its Cash Value, Near-Term Catalysts, No Obvious Bear Thesis

Cyclacel Pharmaceuticals is an oncology company with two major value drivers in Phase 1/2 trials and overdue catalysts. It trades at an $11 million ma more_horizontal


Search within

Pages Search Results: